These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 35723862)
1. An Industry Survey on Managing the Pharmacovigilance System Master File in a Global Environment: The Need for a Pragmatic Approach. Lavery C; Emmott J; Jeck-Thole S; Rouben P; Usher D; van der Spuij W; Woodward L Pharmaceut Med; 2022 Aug; 36(4):233-245. PubMed ID: 35723862 [TBL] [Abstract][Full Text] [Related]
2. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations. Peters T; Soanes N; Abbas M; Ahmad J; Delumeau JC; Herrero-Martinez E; Paramananda M; Piper J; Smail-Aoudia F; van der Spuij W; Veizovic T; Winstanley G; Drug Saf; 2021 Jan; 44(1):17-28. PubMed ID: 33289904 [TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance in pharmaceutical companies: An overview. Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978 [TBL] [Abstract][Full Text] [Related]
4. The Enigma of Pharmacovigilance of Patient Support Programs: A Survey of Marketing Authorization Holders in Europe. Portnoff JM; Lewis DJ Ther Innov Regul Sci; 2017 Jul; 51(4):486-493. PubMed ID: 30227052 [TBL] [Abstract][Full Text] [Related]
5. Negotiating Your Way Through the Vigilance Agreement Maze-is There a Better Way? Corbel-Ecalard C; Kilgour-Christie J; Trun W; Lewis DJ Ther Innov Regul Sci; 2023 Sep; 57(5):1017-1029. PubMed ID: 37270450 [TBL] [Abstract][Full Text] [Related]
6. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Borg JJ; Aislaitner G; Pirozynski M; Mifsud S Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243 [TBL] [Abstract][Full Text] [Related]
7. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review. Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000 [TBL] [Abstract][Full Text] [Related]
8. Issues with regulatory pharmacovigilance in East European countries: the industry perspective. Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561 [TBL] [Abstract][Full Text] [Related]
9. Effects of the COVID-19 Pandemic on Pharmacovigilance Strategy, Systems, and Processes of Large, Medium, and Small Companies: An Industry Survey. Beninger P; Caubel P; Sharma L; Pajovich G; Boyd P Clin Ther; 2022 Sep; 44(9):1225-1236. PubMed ID: 35940940 [TBL] [Abstract][Full Text] [Related]
10. Experiences and Perspectives of Marketing Authorisation Holders towards Medication Safety Monitoring during Pregnancy: A Pan-European Qualitative Analysis. Sillis L; Foulon V; Verbakel JY; Ceulemans M Int J Environ Res Public Health; 2022 Apr; 19(7):. PubMed ID: 35409928 [TBL] [Abstract][Full Text] [Related]
11. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication. Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075 [TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance and the digital world in Italy: presentation of the results of a national survey. Stagi L; Bocchi I; Bianco S; Sirizzotti G; Bernardini D; Calderazzo V; Pirisino G; Grisoni I; Romano S Ther Adv Drug Saf; 2021; 12():2042098620985991. PubMed ID: 33623659 [TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance Agreements: Negotiating Safety Data Exchange Timelines: To Agree to Disagree? That is the Question. Manko Singer W; Pileggi EM; Gibble Y; Lewis DJ Ther Innov Regul Sci; 2023 Sep; 57(5):1050-1061. PubMed ID: 37341970 [TBL] [Abstract][Full Text] [Related]
14. European pharmacovigilance: increasingly outsourced to drug companies. Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153 [TBL] [Abstract][Full Text] [Related]
15. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Tsintis P; La Mache E Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824 [TBL] [Abstract][Full Text] [Related]
16. Risk Communication and the Pharmaceutical Industry: what is the reality? Edwards B; Chakraborty S Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779 [TBL] [Abstract][Full Text] [Related]
17. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa. Narsai K; Williams A; Mantel-Teeuwisse AK South Med Rev; 2012 Jul; 5(1):31-7. PubMed ID: 23093897 [TBL] [Abstract][Full Text] [Related]
18. Chaos to Clarity: Pragmatic Approaches to Overcome Challenges for Successful Implementation of Additional Risk Minimisation Measures in the European Union and the UK by a Marketing Authorisation Holder. Hapani K; Parikh N; Pianka K; Patel H Pharmaceut Med; 2022 Jun; 36(3):173-188. PubMed ID: 35416591 [TBL] [Abstract][Full Text] [Related]
19. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States]. Kato M; Ishikawa H; Okuhara T; Kiuchi T Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625 [TBL] [Abstract][Full Text] [Related]
20. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union. Woodward KN J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]